全文获取类型
收费全文 | 63565篇 |
免费 | 6469篇 |
国内免费 | 2381篇 |
专业分类
耳鼻咽喉 | 138篇 |
儿科学 | 608篇 |
妇产科学 | 260篇 |
基础医学 | 2564篇 |
口腔科学 | 429篇 |
临床医学 | 5590篇 |
内科学 | 7094篇 |
皮肤病学 | 1059篇 |
神经病学 | 2098篇 |
特种医学 | 666篇 |
外国民族医学 | 7篇 |
外科学 | 1878篇 |
综合类 | 8186篇 |
现状与发展 | 5篇 |
一般理论 | 7篇 |
预防医学 | 4688篇 |
眼科学 | 696篇 |
药学 | 29518篇 |
28篇 | |
中国医学 | 3162篇 |
肿瘤学 | 3734篇 |
出版年
2024年 | 180篇 |
2023年 | 1007篇 |
2022年 | 1581篇 |
2021年 | 2223篇 |
2020年 | 2297篇 |
2019年 | 2296篇 |
2018年 | 2324篇 |
2017年 | 2604篇 |
2016年 | 2420篇 |
2015年 | 2440篇 |
2014年 | 4158篇 |
2013年 | 6939篇 |
2012年 | 4250篇 |
2011年 | 4350篇 |
2010年 | 3491篇 |
2009年 | 3093篇 |
2008年 | 2951篇 |
2007年 | 2996篇 |
2006年 | 2691篇 |
2005年 | 2442篇 |
2004年 | 2106篇 |
2003年 | 1931篇 |
2002年 | 1480篇 |
2001年 | 1404篇 |
2000年 | 1088篇 |
1999年 | 889篇 |
1998年 | 788篇 |
1997年 | 737篇 |
1996年 | 599篇 |
1995年 | 566篇 |
1994年 | 479篇 |
1993年 | 406篇 |
1992年 | 465篇 |
1991年 | 398篇 |
1990年 | 315篇 |
1989年 | 257篇 |
1988年 | 256篇 |
1987年 | 246篇 |
1986年 | 187篇 |
1985年 | 198篇 |
1984年 | 171篇 |
1983年 | 124篇 |
1982年 | 111篇 |
1981年 | 88篇 |
1980年 | 58篇 |
1979年 | 59篇 |
1978年 | 68篇 |
1977年 | 46篇 |
1976年 | 48篇 |
1975年 | 48篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
61.
目的 探讨NRP-1单克隆抗体(NRP-1 MAb)的特异性,以及不同剂量的NRP-1 MAb治疗乳腺癌裸鼠移植瘤的疗效。方法 Western blot和共聚焦免疫荧光法检测NRP-1 MAb是否识别MCF7细胞上NRP-1蛋白。将MCF7细胞接种于BALB/c裸鼠皮下建立乳腺癌细胞移植瘤模型,并进行瘤组织传代。传代的肿瘤体积生长至300~500 mm3时,随机分为对照组、NRP-1 MAb低剂量组、中剂量组和高剂量组,每组6只,给药7次。观察荷瘤裸鼠一般状况,测量瘤体大小及裸鼠体重。实验结束时剥离瘤体称重,提取组织蛋白,Western blot检测组织中VEGF蛋白和NRP-1蛋白的表达量。结果 NRP-1MAb成功识别MCF7细胞上的NRP-1蛋白;NRP-1 MAb能够有效抑制MCF7细胞裸鼠移植瘤的生长,低剂量组(1 mg/kg)抑瘤率为47.01%,中剂量组(5 mg/kg)抑瘤率为65.70%,高剂量组(10 mg/kg)抑瘤率为69.19%。。结论 NRP-1 MAb能够识别并有效结合MCF7细胞膜上的NRP-1蛋白,且可抑制MCF7细胞移植瘤的生长,NRP-1 MAb抑制移植瘤的增长可能与下调NRP-1和VEGF表达有关。 相似文献
62.
目前化疗仍为晚期胃癌的标准治疗手段,而多数患者诊断时已接近晚期。近年新兴的免疫治疗手段程序性死亡蛋白-1(PD-1,programmed death l)抗体,通过阻断肿瘤细胞逃避自身免疫机制,重新激活自身免疫对肿瘤的杀伤作用,从而达到肿瘤的治疗作用。针对晚期胃癌的PD-1抗体治疗的临床研究已在国内外开展,大部分均有较好效果。本文对近年免疫治疗中的PD-1抗体在晚期胃癌的重要临床研究进展进行介绍。 相似文献
63.
目的:探讨骨伤科中成药的用药规律,为临床合理用药及新药开发提供参考。方法:以《中国药典》2015年版一部收载的骨伤科类中成药共149个为研究对象,运用频数分析的方法研究其主治病症、所用剂型、各类方剂高频药物、核心药物组成,分析骨伤科中成药用药规律。结果:常用骨伤科中成药中治疗骨关节痹症的最多,其次为跌打损伤和骨关节退行性疾病的中成药;剂型以胶囊剂、片剂、丸剂为主;以活血化瘀药、祛风湿药、补虚药为核心药物组合,各类方剂中三者比例偏重不同。结论:通过对研究结果进行分析,提出了新药研发的方向。 相似文献
64.
Stephen Hanessian 《ACS medicinal chemistry letters》2016,7(1):6-9
Current major advances in drug discovery
can be traced back to
pioneering contributions originating from academics over a century
ago. Living in a symbiotic yet noninvasive coexistence, the academic
community and the pharmaceutical industry have strived, each in their
own way, to develop the modern medicines that benefit humankind today.
The subject is presented from a historical and personal perspective. 相似文献
65.
目的探讨益气化瘀解毒方干预后对Sorafenib获得性耐药人肝癌QGY7702细胞(QGY7702/Sora)增殖及MRP、GST-π和Topo Ⅱ基因表达的影响。方法培养QGY7702/Sora细胞和QGY7702细胞,利用Cell Counting Kit-8(CCK-8)法检测Sorafenib对细胞的半数抑制率浓度(IC50值),计算耐药指数RI;观察益气化瘀解毒方对耐药细胞的增殖影响;采用荧光定量PCR检测药物干预前后2种细胞中MRP、GST-π和Topo Ⅱ基因表达水平。结果亲本细胞和耐药细胞Sorafenib的IC50值分别为(7.993±0.522)μmol/L和(19.651±1.216)μmol/L,RI约为2.5。益气化瘀解毒方可抑制耐药细胞的增殖活性。2种细胞的MRP、GST-π、Topo Ⅱ表达量无明显差异(P>0.05)。Sorafenib组可促进耐药细胞MRP 、GST-π基因的过表达(P<0.05),益气化瘀解毒方组可抑制GST-π基因的过表达(P<0.01),且联合Sorafenib可显著提高Topo Ⅱ基因的表达量(P<0.01)。结论 QGY7702/Sora细胞MRP、GST-π和Topo Ⅱ的表达水平与亲本细胞无显著差异。耐药细胞对Sorafenib敏感性降低与MRP、GST-π过表达相关,而益气化瘀解毒方拮抗Sorafenib耐药与抑制GST-π过表达相关。 相似文献
66.
WHO MULTICENTRE GROWTH REFERENCE STUDY GROUP & Mercedes de Onis 《Acta paediatrica (Oslo, Norway : 1992)》2006,95(S450):96-101
Aim: To examine relationships among physical growth indicators and ages of achievement of six gross motor milestones in the WHO Child Growth Standards population. Methods: Gross motor development assessments were performed longitudinally on the 816 children included in the WHO Child Growth Standards. Six milestones (sitting without support, hands-and-knees crawling, standing with assistance, walking with assistance, standing alone, walking alone) were assessed monthly from 4 until 12 mo of age and bimonthly thereafter until children could walk alone or reached 24 mo. Failure time models were used 1) to examine associations between specified ages of motor milestone achievement and attained growth z scores and 2) to quantify these relationships as delays or accelerations in ages of milestone achievement. Results: Statistically significant associations were noted between ages of achievement of sitting without support and attained weight-for-age, weight-for-length and BMI-for-age z scores. An increase of one unit z score in these indicators was associated with 3 to 6 d acceleration in the respective achievement age. Statistically significant associations also were noted between various milestone achievement ages and growth when 3- or 6-mo and birth length-for-age z scores were entered jointly in the failure time models. In these analyses, one unit z-score increase in length-for-age was associated with 1 to 3 d delay in the respective achievement age.
Conclusion: Sporadic, significant associations were observed between gross motor development and some physical growth indicators, but these were quantitatively of limited practical significance. These results suggest that, in healthy populations, the attainment of these six gross motor milestones is largely independent of variations in physical growth. 相似文献
Conclusion: Sporadic, significant associations were observed between gross motor development and some physical growth indicators, but these were quantitatively of limited practical significance. These results suggest that, in healthy populations, the attainment of these six gross motor milestones is largely independent of variations in physical growth. 相似文献
67.
68.
Theodore C. Bania MD MS Tom Ashar MD Gregory Press MD Patricia M. Carey MD 《Academic emergency medicine》2003,10(7):697-704
Long-term daily use of gamma-hydroxybutyrate (GHB) and related compounds has recently been associated with a withdrawal syndrome. To the best of the authors' knowledge, there are currently no animal models of GHB withdrawal. OBJECTIVES: The authors studied and described the effect of chronic dosing of GHB (3-6 days) on tolerance and withdrawal in a rat model. METHODS: Rats were administered GHB every three hours via intraperitoneal catheter. Groups of rats (2 per group) were dosed with GHB for either 3 (24 doses), 4 (32 doses), 5 (40 doses), or 6 (48 doses) days. The GHB dose was 0.25 g/kg for doses 1-8, 0.75 g/kg for doses 9-12, 1 g/kg for doses 13-16, 1.25 g/kg for doses 17-24, 1.5 g/kg for doses 25-32, 1.75 g/kg for doses 33-40, and 2 g/kg for doses 41-48. Following the last dose of GHB, the rats were scored using a 16-point ethanol intoxication-withdrawal scale rating spontaneous behaviors, response to handling, grooming, and neurological signs. Lower scores indicate intoxication, while higher scores indicate withdrawal. Scores were recorded at hours 0, 1, 2, 3, 4, 5, 6, 9, 12, and 24. RESULTS: Tolerance: Rats dosed with GHB for more days were less intoxicated one hour after their last GHB dose despite receiving higher doses. WITHDRAWAL: The scores for all rats dosed with GHB increased at hours 4 (p = 0.028), 5 (p = 0.037), 6 (p = 0.007), and 9 (p = 0.024) after the last dose, indicating withdrawal. The scores demonstrated a linear increase dependent upon the number of days of GHB dosing at hours 3 (p < 0.000), 4 (p = 0.004), 5 (p = 0.002), and 12 (p = 0.039) as well as prior to the last dose at hour 0 (p = 0.000). No rats developed seizures. CONCLUSIONS: Tolerance and mild withdrawal in rats can be induced by administering intraperitoneal GHB every three hours for 3-6 days. More prolonged dosing and higher doses of GHB may be necessary to induce severe withdrawal. 相似文献
69.
70.